SUSMED,Inc. (TYO:4263)
730.00
+6.00 (0.83%)
Jul 15, 2026, 3:30 PM JST
SUSMED,Inc. Revenue
SUSMED,Inc. had revenue of 139.00M JPY in the quarter ending March 31, 2026, a decrease of -59.71%. This brings the company's revenue in the last twelve months to 274.00M, down -39.51% year-over-year. In the fiscal year ending June 30, 2025, SUSMED,Inc. had annual revenue of 462.00M with 35.09% growth.
Revenue (ttm)
274.00M
Revenue Growth
-39.51%
P/S Ratio
44.79
Revenue / Employee
6.37M
Employees
43
Market Cap
12.27B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 462.00M | 120.00M | 35.09% |
| Jun 30, 2024 | 342.00M | -188.00M | -35.47% |
| Jun 30, 2023 | 530.00M | 214.00M | 67.72% |
| Jun 30, 2022 | 316.00M | 201.00M | 174.78% |
| Jun 30, 2021 | 115.00M | 81.00M | 238.24% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RaQualia Pharma | 3.82B |
| StemCell Institute | 2.81B |
| ReproCELL | 2.23B |
| Immuno-Biological Laboratories | 1.00B |
| Stella Pharma | 323.00M |
| Nano Holdings | 174.00M |
| CellSeed | 161.00M |
| Kubota Pharmaceutical Holdings | 18.78M |